GSK Urges Regulatory Changes To Pull EU Market From Doldrums
This article was originally published in The Tan Sheet
Executive Summary
The time appears right for Rx-to-OTC switches as European Union members struggle to control expanding health budgets in the face of aging populations and the continuing global economic crisis.
You may also be interested in...
Oxytrol, Flomax Switches Show Gap Between U.S., U.K. Pathways
EU centralized switch has proven difficult, with only two drugs making the transition from Rx to OTC in the European Medicines Agency process, and EU member state switches also remain complex. Boehringer’s Flomax U.K. switch and Merck’s Oxytrol for Women in the U.S. underscore differences in the regulatory paths.
Oxytrol, Flomax Switches Show Gap Between U.S., U.K. Pathways
EU centralized switch has proven difficult, with only two drugs making the transition from Rx to OTC in the European Medicines Agency process, and EU member state switches also remain complex. Boehringer’s Flomax U.K. switch and Merck’s Oxytrol for Women in the U.S. underscore differences in the regulatory paths.
GlaxoSmithKline's OTC Garage Sale Includes alli, FiberChoice
GlaxoSmithKline includes the alli weight-loss brand in its planned divestment of international OTCs worth about $813 million in 2010 sales, or 10% of the firm's total Consumer Healthcare business.